Echocardiographic evaluation of cardiac function after cancer chemotherapy

被引：23

作者：

Negishi T. ^{[1
]}

Negishi K. ^{[1
]}

机构：

[1] Menzies Institute for Medical Research, University of Tasmania, Private Bag 23, Hobart

来源：

Journal of Echocardiography | 2018年 / 16卷 / 1期

关键词：

Anthracycline; Cancer therapy-related cardiac dysfunction; Cardiotoxicity; Ejection fraction; Myocardial strain; Trastuzumab;

D O I：

10.1007/s12574-017-0344-6

中图分类号：

学科分类号：

摘要：

Progress in cancer therapy has led to improved prognosis of patients with cancer and thus to a continuous rise of cancer survivors. However, it has simultaneously increased cardiovascular morbidity and mortality rates due to direct and/or indirect side effects of anticancer treatment. Similar to the rapid rise of patients with adult congenital disease, the number of patients suffering or at risk of cardiotoxicity has been steeply increasing and getting an emerging issue. Among the many facets of chemotherapy-induced cardiovascular toxicity, this review attempts to summarize echocardiographic evaluation of cardiac function after cancer chemotherapy by reviewing the definition, risk factors, brief history, limitation of left ventricular ejection fraction and myocardial strain imaging, as well as the limitations of this technique. © 2017, Japanese Society of Echocardiography.

引用

页码：20 / 27

页数：7

共 30 条

[1]

Siegel R., DeSantis C., Virgo K., Et al., Cancer treatment and survivorship statistics, 2012, CA Cancer J Clin, 62, pp. 220-241, (2012)

[2]

Felker G.M., Thompson R.E., Hare J.M., Et al., Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy, New Engl J Med, 342, pp. 1077-1084, (2000)

[3]

Snipelisky D., Park J.Y., Lerman A., Et al., How to develop a cardio-oncology clinic, Heart Fail Clin, 13, pp. 347-359, (2017)

[4]

Martin M., Esteva F.J., Alba E., Et al., Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations, Oncologist, 14, pp. 1-11, (2009)

[5]

Plana J.C., Galderisi M., Barac A., Et al., Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, J Am Soc Echocardiogr, 27, pp. 911-939, (2014)

[6]

Ewer M.S., Lippman S.M., Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity, J Clin Oncol, 23, pp. 2900-2902, (2005)

[7]

Zamorano J.L., Lancellotti P., Rodriguez Munoz D., Et al., 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur Heart J, 37, pp. 2768-2801, (2016)

[8]

Dubost M., Ganter P., Maral R., Et al., A new antibiotic with cytostatic properties: rubidomycin, C R Hebd Seances Acad Sci, 257, pp. 1813-1815, (1963)

[9]

Tan C., Tasaka H., Yu K.P., Et al., Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia, Cancer, 20, pp. 333-353, (1967)

[10]

Jensen B.V., Skovsgaard T., Nielsen S.L., Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients, Ann Oncol, 13, pp. 699-709, (2002)

← 1 2 3 →